lifestyle.utv.ie

Author: Beam Therapeutics

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

May 13, 2026
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

May 12, 2026
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

May 7, 2026
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

May 1, 2026
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

April 30, 2026
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

February 24, 2026
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

February 24, 2026
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

February 23, 2026